The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move that boosts visibility for small-cap biotech firms, Elicio Therapeutics (Nasdaq: ELTX) was added to the Russell 2000 and Russell 3000 indexes effective after the U.S. market close on June 26, 2026, according to a company announcement. The inclusion is expected to attract passive fund inflows, potentially supporting the stock which trades at low levels.
Elicio Therapeutics shares closed at $4.00 on June 26, 2026, up from an intraday low of $3.63, per market data. Russell index additions typically lead to higher trading volumes and institutional interest, especially for thinly traded small-cap stocks.
Sign in to access this content
Sign InAt the June 26 close, ELTX traded at $4.00, near its session high of $4.10, reflecting cautious optimism. Investors will watch for upcoming clinical milestones and whether the index inclusion translates into sustained liquidity gains.